Objective The aim of this study was to assess the changes in the clinical parameters during intragastric balloon therapy for Japanese obese patients. Methods Between March 2009 and September 2010, 8 patients underwent intragastric balloon therapy at our hospital. The visceral fat area, liver volume and the liver-spleen ratio were measured by computed tomography. Blood examination and computerized tomography were performed before the balloon placement, and at 1, 3 and 6 months after the balloon placement in all of the patients. Results Eight patients (5 males and 3 females, median age, 39 years; median BMI, 44.0 kg/m 2 ) underwent intragastric balloon therapy without severe complications. The median weight loss was 8.6 kg, mean BMI loss was 2.8 kg/m 2 , and the percent excess weight loss was 14.8% at 6 months after the balloon placement. The body weight and liver volume decreased significantly during the first month, and the results were maintained at the same levels until after the second month. The liver-spleen ratio also improved significantly during the first month, but worsened again during the last 3 months. The visceral fat area showed no significant differences during the treatment as well as no differences in liver enzymes, glucose and lipid metabolism. Conclusion Intragastric balloon therapy achieved a moderate effect in weight and liver volume reduction during the early months of the treatment. Intragastric balloon therapy may have a role as a minimally invasive method for pretreatment before laparoscopic surgery.
Introduction
The prevalence of overweight people is increasing around the world, and according to an estimate by the World Health Organization (WHO), more than 1.6 billion people are currently overweight and 400 million are obese around the world (1) . In parallel, the prevalence of obesity-related diseases, such as type 2 diabetes, hypertension, dyslipidemia, respiratory disorders and osteoarthropathy, are also increasing and becoming global public health problems. In the United States, relative to the estimates for subjects with a BMI in the range of 20 to 24.9, the mean annual total health maintenance costs were 25% greater for those with a BMI in the range of 30 to 34.9 (rate ratio, 1.25; 95% confidence interval, 1.10-1.41), and 44% greater for those with a BMI of 35 or greater (rate ratio, 1.44; 95% confidence interval, 1.22-1.71) (2) . In Japan, westernization of the dietary habits has led to an increase in the incidence of obesity among males (3) .
The outcomes of diet therapy, exercise, behavioral therapy and medication have not been sufficiently satisfactory, and in studies conducted in Europe and the United States, intragastric balloon therapy and bariatric surgery have been shown to result in substantial, long-term weight reduction. In Japan, Kawamura and Ochiai (4) introduced gastric bypass in 1982 as the first bariatric surgery, and intragastric balloon therapy was introduced by Ohta et al (5) . However, there are only a few reports of intragastric balloon therapy in Japanese patients and no reports to date of the timecourse of the effects of intragastric balloon therapy. The aim of this study was to conduct a retrospective assessment of the changes in the body weight, liver volume, liver function and visceral fat area over time in subjects undergoing intragastric balloon therapy.
Materials and Methods

Patient characteristics
Between March 2009 and September 2010, 8 Japanese patients underwent intragastric balloon therapy at our hospital. The subjects comprised 5 males and 3 females, with a median age of 39 years (range 19-61), median height of 169.5 cm (range 153.5-176.5), median weight before intragastric balloon placement of 117.6 kg (range 104.2-160.0), median BMI of 44.0 kg/m 2 (range 38.2-55.4), and median excess weight of 54.4 kg (range 47.6-98.9). All of the patients were diagnosed as having one or more of the following obesity-related diseases: glucose intolerance (4/8, 50.0%; diagnosed based on the criteria of Japan Diabetes Society as fasting plasma glucose (FPG) !126 mg/dL and/or 2-hour plasma glucose !200 mg/dL and/or HbA1c >6.5%), hypertension (6/8, 75.0%; diagnosed according to the guideline of the Japanese Society of Hypertension as systolic blood pressure !140 mmHg and/or diastolic blood pressure !90 mmHg), dyslipidemia (7/8, 87.5%; diagnosed according to the guideline of the Japan Atherosclerosis Society, serum LDL cholesterol !140 mg/dL or HDL cholesterol <40 mg/ dL or TG !150 mg/dL), hyperuricemia (4/8, 50.0%; diagnosed according to the guideline of the Japanese Society of Gout and Nucleic Acid Metabolism, UA >7.0 mg/dL), metabolic syndrome [6/8, 75 .0%; defined based on the criteria of the Japanese Society of Internal Medicine as a large waist circumference (measured at the umbilical level) of !85 cm for men and !90 cm for women plus two or more of the following compoments: 1) serum TG !150 mg/dL and/or HDL cholesterol <40 mg/dL, 2) FPG !110 mg/dL, and 3) blood pressure !130/85 mmHg].
Intragastric balloon treatment
The BioEnterics Intragastric Balloon (BIB , inamed, Health-Allergan Medical, Santa Barbara, CA, USA) was used in all patients. The inclusion criteria were: 1) morbid obesity (BMI !35 kg/m 2 ); 2) the presence of one or more obesity-related diseases, including type 2 diabetes, hypertension, dyslipidemia, respiratory disorders and osteoarthropathy; 3) failure of previous therapeutic lifestyle modification for at least 6 months. The exclusion criteria were: 1) active peptic ulcer; 2) inflammatory bowel disease; 3) cancer; 4) previous gastrectomy; 5) hiatal hernia (>5 cm in diameter); 6) pregnancy; 7) psychological disorders inadequately controlled by drug treatment; 8) chronic therapy with aspirin, anti-inflammatory agents, anticoagulants or steroids.
The BIB placement was performed under intravenous sedation (midazolam). After the BIB system was placed through the mouth, an endoscope was inserted. The balloon was positioned in the gastric fundus under endoscopic guidance, inflated with saline (1,000 mL of saline mixed with 10 mL of 1% methylene blue) until the balloon distended to fill the gastric fundus. The filling catheter was then removed, and the procedure was completed. All patients were kept fasting in the hospital for at least 2 days, to watch for complications such as abdominal pain and vomiting. They were discharged when they could manage liquid diet. At 6 months after the BIB replacement, the balloon was removed under endoscopic guidance.
Blood examination and abdominal computerized tomography were performed before the balloon placement, and at 1, 3 and 6 months after the balloon placement in all the patients to distinguish prolapse of the balloon or any other complications.
Computed tomography protocol
Liver volume and visceral fat area were measured on computed tomographic images. Unenhanced axial images through the liver were obtained at 5.0-mm collimation, 12.0mm/rotation table speed (B31f mode, pitch 0.85), 140 kV (p), and auto mA (Somaton Sensation 16; SIEMENS). Images were reconstructed at 7-mm increments. All patients underwent abdominal computed tomography after overnight fasting for at least 8 hours.
Measurement of the liver volume
We hand-traced only the outline of the liver, excluding the inferior vena cava and major vessels as shown in Fig. 1 . Liver volume was calculated using the 'sum of areas' method: areas (cm 2 ) × reconstitution index (cm)=volume (cm 3 ) per axial section (6) .
Measurement of the liver-spleen ratio
CT numbers (in Hounsefield units) in a region of interest (ROI) of 400 mm 2 were measured at 4 points in the periphery of the liver (each hepatic segment except the caudate lobe) and an arbitrary point in the spleen. The mean numbers were used to determine the liver-spleen (L/S) ratio.
Measurement of the visceral fat area
According to the criteria of metabolic syndrome established at the Japanese Society of Internal Medicine, the intra-abdominal visceral fat area was measured at the middle level between lower edge of costal arch and upper edge of anterior iliac crest by a standardized method, in terms of the CT number using the computer software, Fat Scan (East Japan Institute of Technology Co., Ltd.). In brief, a region of interest was defined in the subcutaneous fat layer by tracing its contour on each scan, and the attenuation range for fat tissue was measured in terms of the CT number (in Hounsfield units).
Statistical analysis
Statistical comparisons were made using Friedman multiple comparisons and Wilcoxon's signed-rank test. The results were considered significant at p<0.05. The statistical analyses were performed using the StatView program (SAS Institute, Cary, NC, USA).
Ethics
The study was conducted in accordance with the Declaration of Helsinki, and with the approval of the Ethics Committee of Yokohama City University School of Medicine. We obtained written informed consent from each of the patients.
Results
The intragastric balloon placement and removal were performed without severe complications in all patients. After the placement, nausea or vomiting occurred in 4 patients (50.0%), and epigastric pain in 1 patient (12.5%), all of which improved within a few days. None of the patients required prolongation of the hospital stay or premature removal of the balloon. The intragastric balloon treatment was completed as per protocol in all patients, and the median weight loss, BMI and percent excess weight loss (%EWL) at 6 months were 8.6 kg, 2.8 kg/m 2 and 14.8%, respectively, and the changes of medication are shown in Table 1 .
We analyzed the clinical parameters as shown in Table 2 . The changes in the body weight, visceral fat area, liver volume, L/S ratio and liver function were assessed and the body weight, liver volume decreased significantly during the first month, and the results were maintained until after the second month. The L/S ratio also improved significantly during the first month, but worsened again during the last 3 months of the study. There was no significant difference in visceral fat area throughout the 6 months of treatment ( Fig. 2-6 ). Among the serum AST, ALT, ALP, γ-GTP, glucose and lipid metabolism levels, there were no significant differences during the treatment. [Fasting plasma glucose (FPG) was measured excluding insulin-treated patients, and HOMA-IR was measured excluding insulin-treated patients and the patients whose FPG were above 140 mg/dL.] Among the plasma adipokines, leptin significantly decreased during the first month, and adiponectin showed no significant difference throughout the 6 months ( Fig. 7, 8) . The individual %EWL during the 6-month treatment period and 6month follow-up period is shown in Fig. 9 . Except for the patient who underwent a second intragastric balloon therapy 1 month after the removal of the first intragastric balloon, all but one patient gained back the weight after the treatment.
Discussion
According to recent reviews about the site differences in fat loss as a proportion of the initial levels, a greater loss of visceral adipose tissue as compared to the relative decrease in the total body adiposity is observed, regardless of the intervention applied to reduce the body weight (7) . Lewis et al reported that in 18 morbidly obese patients who completed 6 weeks of very low calorie diet, a 9.1 kg reduction of body weight, 4.0 kg/m 2 reduction of the BMI, 14.7% reduction of the liver volume and 43% reduction of the liver fat were observed, as measured by magnetic resonance imaging (6) . The results of the present study were consistent with these previous reports; the reduction rate of liver volume and of the visceral fat area during the first month were 7.8% and 15.2%, greater than that of the total body weight of 7.4%. The reduction of the liver volume and visceral fat area slackened after the second month, in parallel with the reduction of the body weight.
The median L/S ratio showed significant difference during the treatment and interestingly, it improved during the first month, but worsened again during in the last 3 months. Despite the variation of liver volume and L/S ratio, the serum levels of AST, ALT, ALP and γ-GTP did not show significant differences. One reason for the discrepancy between the result and these supposed changes may be that most patients had normal liver function or slight liver dysfunction, and only 1 patient had severe hepatic dysfunction, with AST, ALT and γ-GTP levels of over twice the normal upper limit. More patients with severe hepatic dysfunction, as well as se- vere glucose intolerance and lipid metabolism may show larger improvement of the liver function during intragastric balloon therapy. In bariatric surgery, infectious complications (8) and diffi-culties in intubation or ventilation during anesthesia (9) have been regarded as major problems. Recently, many bariatric surgeons have tended to prefer sleeve gastrectomy, gastric bypass and gastric banding via laparoscopy rather than the Meanwhile, previous reports have suggested that preoperative weight reduction with intragastric balloon placement resulted in improvement of the conversion rate from laparoscopic to open surgery, and improvement of the complication rate during laparoscopic gastric band placement. In the study of intragastric balloon therapy for 16.8 weeks by Weiner et al on 14 patients, the mean weight loss was 18.1 kg, and the conversion and complication rates were 0% (11) . Bussetto et al showed that in 43 patients who underwent intragastric balloon therapy for 16.4 days, the percent excess weight loss was 26.1%, and the conversion and complication rates were 0%, whereas the conversion rate was 16.3% and the complication rate, 7.0% in the control groups (12) . These previous reports suggest that preoperative intragastric balloon therapy may likely produce favorable reduction of the visceral fat area, including the liver and omental fat, thereby causing improvement of the conversion rate. In the present study, the liver volume and visceral fat decreased during the first month, and the results were maintained until after the second month. If the volume of the liver and visceral fat were the biggest factors affecting the safety during the perioperative period, intragastric balloon therapy for a few weeks may serve as a useful preparation procedure prior to laparoscopic bariatric surgery.
In the present study, excersise therapy and medication were not used in combination and it may be one of the rea- sons that visceral fat area did not show a significant decrease. Additional medication, such as mazindol, or strict behavioral therapy may also be considered.
In conclusion, intragastric balloon therapy achieved a moderate effect in weight and liver volume reduction during the early months of the treatment. Although it was insufficient to improve obesity-related metabolic abnormalities and almost all of the patients gained back the weight, the intragastric balloon therapy may have a role as a minimally invasive pretreatment before laparoscopic surgery. Prospective assessment of combination therapy with intragastric balloon therapy and exercise, strict behavioral therapy or medication is expected.
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